Document:

exv10w2

Exhibit 10.2

	 	 	 

	BIOCRYST PHARMACEUTICALS . INC .

	 	Jon P. Stonehouse 
	4505 EMPEROR BOULEVARD. SUITE 200

	 	President & CEO
	DURHAM. NC 27703
	 	 
	919-859-7908 919-859-1314 FAX
	 	 
	 
	 	 
	2190 PARKWAY LAKE DRIVE
	 	 
	BIRMINGHAM . AL 35244
	 	 
	205-444-4648 205-982 -3072 FAX
	 	 
	 
	 	 
	www.biocryst.com
	 	 
	jstonehouse@biocryst.com
	 	 

May 23, 2011

Mr. Thomas R. Staab

II, CPA 520 Tharps Lane

Raleigh, NC 27614

Dear Mr. Staab:

     On behalf of BioCryst Pharmaceuticals, Inc., a Delaware corporation (“BioCryst” or the
“Company”), we are very excited to offer you the position of Senior Vice President and Chief
Financial Officer. We, along with the other members of the Company’s Board of Directors (the
“Board”), and the Company’s management team, are all very impressed with you and what you will
bring to the Company. We believe that with your background, you will make significant
contributions to the success of the Company.

     This letter agreement (the “Agreement”) will serve to confirm our agreement with respect to
the terms and conditions of your employment.

1. Term of Employment. Subject to the terms and conditions of this Agreement, BioCryst
hereby employs Thomas R. Staab (the “Employee”), effective
July 1st, 2011, as Senior
Vice President and Chief Financial Officer of BioCryst, and Employee hereby accepts such
employment. Employee shall commence employment at the Company’s Durham, North Carolina office.
The Employee shall not, during the term of his employment, engage in any other business activity
that would interfere with, or prevent him from carrying out, his duties and responsibilities
under this Agreement. BioCryst hereby agrees and acknowledges that any compensation which the
Employee receives from participation in such allowable activities shall be outside the scope of
this Agreement and in addition to any compensation received hereunder. The term of employment
of Employee under this Agreement shall commence as of July
1st, 2011, and
shall terminate on June 30, 2015 unless earlier terminated in accordance with the provisions of
paragraph 4 hereof. In the event Employee is retained by the Company as Senior Vice President
and Chief Financial Officer past June 30, 2015, the terms of his employment shall continue to be
governed by this Agreement unless otherwise provided by the Board.

2. Basic Full-Time Compensation and Benefits.

     (a) As basic compensation for services rendered under this Agreement, Employee shall
be entitled to receive from BioCryst, a salary of $30,800.33 per month ($370,000 per
annum) payable in bi-monthly payments for each calendar month during the term of this
Agreement, beginning July 1, 2011. This salary will be reviewed annually by the Board of
Directors and may be raised at the discretion of the Board.

     (b) In addition to the basic compensation set forth in (a) above, Employee shall be
eligible to earn a cash bonus, payable as soon as reasonably practicable in the calendar
year following each calendar year during the term of this Agreement, based on the
Company’s achievement of performance related goals proposed by management and approved by
the Board for the Company’s applicable fiscal

 

 

Thomas R. Staab, II, CPA

Page 2

May 23,2011

year (the “Fiscal Year”). The bonus actually earned, if any, shall be based on a
target amount equal to 30% of the base compensation earned by executive during such
Fiscal Year (the “Target Amount”), and shall be pro-rated based on the degree to which
the performance goals have been achieved, subject to a minimum level of achievement
proposed by management and approved by the Board. The Target Amount for the 2011 Fiscal
Year shall be prorated based on Employee’s base compensation earned during 2011. The
Board may, in its discretion, approve a bonus in excess of the Target Amount if the
performance goals have been exceeded. Employee must be employed through April 1, of the
next succeeding Fiscal Year in order to receive the annual bonus for each Fiscal Year.

     (c) In addition to the basic compensation set forth in (a) and (b) above, Employee
shall be entitled to receive such other benefits and perquisites provided to other
executive officers of BioCryst which benefits may include, without limitation,
reasonable vacation (currently 4 weeks), sick leave, medical benefits, life insurance,
and participation in profit sharing or retirement plans.

     (d) In addition to the compensation set forth in paragraphs 2(a), (b) and (c)
above, the Board of Directors of BioCryst may from time to time, in its discretion, also
grant such other cash or stock bonuses to the Employee either as an award or as an
incentive as it shall deem desirable or appropriate.

3. Initial Equity Awards. In connection with Employee’s execution of this Agreement, Employee
shall be issued initial equity incentive awards as follows:

     (a) The Company shall grant to Employee an option to purchase 200,000 shares of the
Company’s common stock (“Common Stock”), with an exercise price equal to the fair market
value of the Common Stock on the date of the grant, which option shall vest and become
exercisable in accordance with paragraph 3(d) below. The option will be an “incentive
stock option” up to the maximum number of shares that may be covered under an incentive
stock option pursuant to the tax code.

     (b) The award set forth in paragraph 3(a) above will vest, contingent on Employee’s
continued provision of services to the Company on each respective vesting date, over a
period of 4 years as follows: The Option will initially become exercisable for 25% of the
Optioned Shares upon Optionee’s completion of twelve (12) months of Service (as defined
in the Standard Stock Option Agreement) measured from the Grant Date and will become
exercisable for the balance of the Optioned Shares at the rate of 25% of the Optioned
Shares upon Optionee’s completion of each additional year of Service measured from the
first anniversary of the Grant Date for the following three years until fully vested on
the fourth anniversary of the grant.

     (c) The Company shall grant to Employee 25,000 restricted shares of the Company’s
Common Stock, as described and granted pursuant to the BioCryst Pharmaceuticals, Inc.,
Stock Incentive Plan. Subject to Employee’s continuous employment with or service to the
Company from the date of grant thru the Vesting Date (12 months from date of hire), the
transfer restrictions on the restricted shares shall lapse and the restricted shares
shall vest and no longer be subject to forfeiture.

     (d) The stock option awards set forth in paragraph 3(a & c) above shall be granted
under and subject to the terms of the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan
(the “Stock Incentive Plan”). All awards shall be subject to the terms of specific award
agreements between the Employee and the Company, which Employee will be required to
execute as a condition of the grants.

4. Termination.

     (a) If Employee’s employment is terminated as a result of (i) the expiration of the
stated term of this Agreement, (ii) the Employee’s resignation, (iii) the
Employee’s death, (iv) by the Company for Cause, or (v) by the Company as a result of
Disability, Employee will receive base salary, as well as any accrued but unused vacation
(if applicable) and other compensation, earned through the effective termination date,
and no additional compensation, except as set forth in Section 4(d) below.

 

 

Thomas R. Staab, II, CPA

Page 3

May 23,2011

     For all purposes under this Agreement, a termination for “Cause” shall mean a
determination by the Board that Employee’s employment be terminated for any of the
following reasons: (i) failure or refusal to comply in any material respect with lawful
policies, standards or regulations of Company; (ii) a violation of a federal or state law
or regulation applicable to the business of the Company; (iii) conviction or plea of no
contest to a felony under the laws of the United States or any State; (iv) fraud or
misappropriation of property belonging to the Company or its affiliates; (v) a breach in
any material respect of the terms of any confidentiality, invention assignment or
proprietary information agreement with the Company or with a former employer, (vi)
failure to satisfactorily perform Employee’s duties after having received written notice
of such failure and at least thirty (30) days to cure such failure, or (vii) misconduct
or gross negligence in connection with the performance of Employee’s duties .

     “Disability” shall mean the inability of Employee to perform his duties hereunder by
reason of physical or mental incapacity for ninety (90) days, whether consecutive or not,
during any consecutive twelve (12) month period.

     (b) If the Company terminates Employee’s employment without Cause, it shall provide
written notice of termination to Employee, along with any base salary and accrued but
unused vacation or other compensation earned through the effective termination date, and,
conditioned on Employee (a) signing and not revoking a release of any and all claims, in
a form prescribed by the Company, and (b) returning to the Company all of its
property and confidential information that is in Employee’s possession, Employee will
receive the following: (i) continuation of base salary for I year beyond the effective
termination date, payable in accordance with the regular payroll practices of the
Company; (ii) payment of Employee’s target bonus in effect for the fiscal year of
termination, payable in equal installments over the regularly scheduled payroll periods
of the Company for the one year following the effective date of termination; and (iii) if
Employee elects to continue health insurance coverage under the Consolidated Omnibus
Budget Reconciliation Act of 1985, as amended (“COBRA”) following termination of
employment, the Company shall pay the monthly premium under COBRA until the earlier of
(x) 6 months following the effective termination date, or (y) the date upon which
Employee commences employment with an entity other than the Company. Employee will notify
the Company in writing within 5 days of your receipt of an offer of employment with any
entity other than the Company, and will accordingly identify the date upon which you will
commence employment in such writing.

     (c) If, during Employee’s employment with the Company, there is a Change of
Control, all equity awards granted to Employee under paragraph 3 and otherwise shall
vest in full. In addition, if the Company terminates Employee’ s employment without
Cause or Employee is Constructively Terminated within 6 month s of the Change in
Control, then Employee will be eligible to receive the benefits provided in paragraph
4(b), under the terms and conditions set forth in that paragraph .

     “Change
of Control” shall be defined as (i) a merger or consolidation in which the
Company is not the surviving entity, except for a transaction the principal purpose of
which is to change the State of the Company’s incorporation; (ii) the sale, transfer or
other disposition of all or substantially all of the assets of the Company in liquidation
or dissolution of the Company; (iii) any reverse merger in which the Company is the
surviving entity but in which securities possessing more than fifty percent (50%) of the
total combined voting power of the Company’s outstanding securities are transferred
to a person or persons different from the persons holding those securities
immediately prior to such merger; (iv) any person or related group of persons (other than
the Company or a person that directly or indirectly controls, is controlled by, or is
under common control with, the Company) directly or indirectly acquires beneficial
ownership (with in the meaning of Rule l3d-3 of the 1934 Act) of securities possessing
more than fifty percent (50%) of the total combined voting power of the Company’s
outstanding securities pursuant to a tender or exchange offer made directly to the
Company’s stockholders; or (v) a change in the composition of the Board over a period of
twenty-four (24) consecutive months or less such that a majority of the Board members
(rounded up to the next whole number) ceases, by reason of one or more contested
elections for Board membership, to be comprised of individuals who either (A) have been
Board members continuously since the beginning of such period or (B) have been elected or
nominated for election as Board members during such period

 

 

Thomas R.
Staab, II, CPA

Page 4

May 23, 2011

by at least two-thirds of the Board members described in clause (A) who were still
in office at the time such election or nomination was approved by the Board.

     “Constructive Termination” shall mean a resignation of employment within 30 days of
the occurrence of any of the following events which occurs within 6 months following a
Change of Control: (i) a material reduction in Employee’s responsibilities; (ii) a
material reduction in Employee’s base salary, unless such reduction is comparable in
percentage to, and is part of, a reduction in the base salary of all executive officers
of the Company; or (iii) a relocation of Employee’s principal office to a location more
than 50 miles from the location of Employee’s principal office immediately preceding a
Change of Control.

     (d) If (i) Employee remains an employee of the Company after the expiration of the
four year term of this Agreement; and (ii) within 6 months thereafter, Employee resigns
as a result of a material and adverse change in the Company’s business, then Employee
shall be entitled to receive the severance benefits on the terms and conditions specified
in paragraph 4(b) above .

     (e) In the event (i) any payments described in paragraphs 4(b), (c) or (d) above
would be “deferred compensation” subject to Section 409A of the Internal Revenue Code of
1986, as amended (the “Code”); and (ii) Employee is a “specified employee” (as defined in
Code Section 409A(2)(B)(i)), such payments shall, to the extent required by Code Section
409A, be delayed for the minimum period and in the minimum manner necessary to avoid the
imposition of the tax required by Code Section 409A.

5. Non-Competition; Proprietary Information and Inventions.

     (a) Proprietary Information and Inventions Agreement. As a condition precedent to
the employment of Employee by the Company, Employee shall execute the Company’s standard
Proprietary Information and Inventions Agreement, attached hereto as Exhibit A.

     (b) Non-Competition Agreement. The Employee agrees that for one (I) year
following the termination of this Agreement by reason of the voluntary termination by the
Employee, without cause on the part of BioCryst, the Employee shall not become
the Chief Financial Officer or become a key executive of another for-profit business
enterprise whose activities are at such time directly competitive with Biofryst.

     (c) Equitable Remedies. Employee acknowledges and recognizes that a violation of
this paragraph by Employee may cause irreparable and substantial damage and harm to
BioCryst or its affiliates, could constitute a failure of consideration, and that money
damages will not provide a full remedy for BioCiyst for such violations. Employee agrees
that in the event of his breach of this paragraph, BioCryst will be entitled, if it so
elects, to institute and prosecute proceedings at law or in equity to obtain damages with
respect to such breach, to enforce the specific performance of this paragraph by
Employee, and to enjoin Employee from engaging in any activity in violation hereof.

6. Miscellaneous.

     (a) Entire Agreement. This Agreement, including the exhibits hereto, constitutes
the entire agreement between the parties relating to the employment of the Employee by
BioCryst and there are no terms relating to such employment other than those contained in
this Agreement. No modification or variation hereof shall be deemed valid unless in
writing and signed by the parties hereto . No waiver by either party of any provision or
condition of this Agreement shall be deemed a waiver of similar or dissimilar provisions
or conditions at any time.

     (b) Assignability. This Agreement may not be assigned without prior written consent
of the parties hereto. To the extent allowable pursuant to this Agreement, this Agreement
shall be binding upon and shall inure to the benefit of each of the parties hereto and
their respective executors, administrators, personal representatives, heirs, successors
and assigns.

 

 

Thomas R. Staab, II, CPA

Page 5

May 23,2011

     (c) Notices. Any notice or other communication given or rendered hereunder by any
party hereto shall be in writing and delivered personally or sent by registered or
certified mail, postage prepaid, at the respective addresses of the parties hereto as set
forth below.

     (d) Captions. The section headings contained herein are inserted only as a matter of
convenience and reference and in no way define, limit or describe the scope of this
Agreement or the intent of any provision hereof.

     (e) Taxes. All amounts to be paid to Employee hereunder are in the nature of
compensation for Employee’s employment by BioCryst, and shall be subject to withholding,
income, occupation and payroll taxes and other charges applicable to such compensation.

     (f) Governing Law. This Agreement is made and shall be governed by and construed in
accordance with the laws of the State of Alabama without respect to its conflicts of law
principles.

     (g) Date. This Agreement is dated as of May 23, 2011.

     If the foregoing correctly sets forth our understanding, please signify your acceptance of
such terms by executing this Agreement, thereby signifying your assent, as indicated below.

	 	 	 	 	 
	 	Yours very truly,

BIOCRYST PHARMACEUTICALS, INC.

 	 
	 	By:  	/s/ Jon P. Stonehouse
 	 
	 	 	Jon P. Stonehouse 	 
	 	 	President & Chief Executive Officer

Address:

4505 Emperor Blvd., Suite
200 
Durham, NC 27703 	 
	 

     AGREED AND ACCEPTED, as of this 25th day of May, 2011

	 	 	 	 	 
	 	 	 
	 	By:  	
/s/ Thomas R. Staab II, CPA
 	 
	 	 	Thomas R. Staab II, CPA 	 
	 
	 	 	Address:

520 Tharps Lane

Raleigh, NC 27703 	 

 

 

	 	 	 	 	 

Exhibit A

(Proprietary Information and Inventions Agreement)

EMPLOYEE’S PROPRIETARY INFORMATION AND INVENTIONS

AGREEMENT

I, Thomas R. Staab, recognize that BioCryst Pharmaceuticals. Inc., a Delaware corporation
(hereinafter the
“Company”, is engaged in a continuous program of research, development, and product; on respecting
its business, present and future. including fields generally related to its business.

I understand that:

	A.	 	As part of my employment by the Company I will faithfully and diligently serve and
endeavor to further and safeguard the interests of the Company and I recognize that I am
expected to make new contributions and inventions of value to the
Company;
	 
	B.	 	My employment creates a relationship of confidence and trust between me and the Company with
respect to any information:

	 	1.	 	Applicable to the business of the Company: or
	 
	 	2.	 	Applicable to the business of any client or customer of the Company which may be made
known to me by the Company or by any client or customer of Company or learned by me during
the period of my employment.

	C.	 	The Company possesses and will continue to possess information that has been
created, discovered, developed, or otherwise become known to the Company (including without
limitation information created, discovered, developed, or made known by me during the period of
or arising out of my employment by the Company) and/or in which property rights have been
assigned or otherwise conveyed to the Company, which information has commercial value in the
business in which the Company is or may be engaged. All of the aforementioned information is
hereinafter called “Proprietary Information.” By way of illustration, but not limitation
Proprietary Information includes trade secrets, processes, formulas, data and know-how,
improvements, inventions, techniques, marketing plans, strategies, forecasts. and customer lists.

	 	 	In consideration of my employment or continued employment, as the case may be, by the
Company and the compensation received by me from the Company from
time to time. I
hereby agree as follows:

	 	1.	 	All Proprietary Information shall be the sole property of the Company and its assigns,
and the Company and its assigns shall be the sole owner of all patents and other rights,
title and interest in connection therewith. I hereby assign to the Company any and all
rights I may have or acquire in such Proprietary Information and/or patents. At all times,
both during my employment by the Company and after its termination, I will keep in
confidence and trust all Proprietary Information, and I will not use or disclose any
Proprietary Information or anything relating to it without the prior written consent of the
Company, except as may be necessary in the ordinary course of performing my duties as an
employee of the Company.
	 
	 	2.	 	I agree that, during the period of my employment by the Company, I will not, without
the Company’s express prior written consent, engage in any employment or consulting other
than for the Company. In the event of the termination of my
employment by me or by the Company for any reason, I will promptly deliver to the Company
all documents and data of any nature pertaining to my work with the Company and I will not
take with me any documents or data of any description or any reproduction of any
description containing or pertaining to any Proprietary Information.
	 
	 	3.	 	I will promptly and fully disclose to the Company, or any persons designated
by it. all improvements, inventions, formulas. processes, techniques, know-how, and data,
whether or not patentable, copyrightable, or otherwise protectable as property, made or
conceived or reduced to practice or learned by me, either alone or jointly with others,
during the period of my employment by the Company which are related to or useful in the
business of the Company, or result from tasks assigned me by the Company or result from use
of premises owned, leased, or contracted for by the Company (all said improvements,
inventions, formulas, processes, techniques, know-how, and data shall be collectively
hereinafter called “Inventions”). I agree to

 

 

	 	 	 	keep complete , accurate, and authentic accounts, notes, data, and records of all
Inventions in the manner and form requested by the Company, which accounts, notes, data, and
records shall be and remain the sole property of the Company. I agree to surrender the same
promptly to the Company upon its request or, in the absence of such a request, upon the
termination of my employment by the Company .

	 	4.	 	I agree that all Inventions are and shall be the sole property of the Company and
its assigns, and that the Company and its assigns shall be the sole owner of all patents
and other rights in connection therewith . I hereby assign to the Company any and all
rights I may have or acquire in or to such Inventions and patents. I further agree as to
all such Inventions to assist the Company in every proper way (but at the Company’s
expense) to obtain and from time to time enforce patents, including amendments, extensions, and continuations of said patents on said Inventions in any and all countries, and to
that end I will execute all documents for use in applying for and for obtaining such
patents, amendments, extensions. and continuations and enforcing same, as the Company may
desire , together with any assignments thereof to the Company or persons designated by it.
My obligation to assist the Company in obtaining and enforcing patents, amendments,
extensions, and continuations for such Inventions in any and all countries shall continue
beyond the termination of my employment, but the Company shall compensate me at a reasonable rate after such termination for time actually spent by me at the Company’s request on
such assistance.
	 
	 	5.	 	As a matter of record I attach hereto a complete list of all Inventions or
improvements relevant to the subject matter of my employment by the Company which have
been conceived, made, or reduced to practice by me, alone or jointly with others, prior
to my engagement by the Company which I desire to remove from the operation of this
Agreement. I covenant that such list is complete . If no such list is attached to this
Agreement, I represent that I have no such Inventions and improvements at the time of
signing this Agreement.
	 
	 	6.	 	I represent that my performance of all of the terms of this Agreement and as an
employee of the Company does not and will not breach any agreement to keep in confidence
Proprietary Information acquired by me in confidence or in trust prior to my employment by
the Company. I have not entered into, and I agree that I will not enter into, any
agreement either written or oral, in conflict herewith.
	 
	 	7.	 	I understand that, as part of the consideration of the offer of employment extended to me
by the Company or of my continued employment by the Company, as the case may be, I will
not bring, have not brought, with me to the Company and I will not use, have not used, in
the performance of my responsibilities at the Company, materials or documents of a former
employer, unless I have obtained written authorization from the former employer for their
possession and use. Accordingly, this is to advise the Company that the only materials
that I will bring to the Company or use in my employment are identified on the attached
sheet (Exhibit A) and, as to each such item, I represent that I have obtained,
prior to the effective date of my employment with the Company, written authorization for
their possession and use in my employment with the Company . I also understand
that, in my employment with the Company . I am not to breach any obligation of
confidentiality that I have to former employers, and I agree that I shall fulfill all such
obligations during my employment with the Company .
	 
	 	8.	 	This Agreement shall be effective as of the first day of my employment by the
Company, namely: July 1, 2011. I understand and agree that this Agreement is not a
contract of employment and that my employment by the Company is, for all purposes, “at
will.”
	 
	 	9.	 	This Agreement shall be binding upon me, my heirs, executors, assigns ,
administrators, and other legal representatives and shall inure to the benefit of the
Company, its successors and assigns.

			
	 	 	 
	DATED: May 25, 2011
	 	Employee: [ILLEGIBLE]

ACCEPTED AND AGREED TO:

BIOCRYST PHARMACEUTICALS, INC.

	 	 	 	 	 
	 	 
	By:  	/s/  [ILLEGIBLE]
 	 
	 	AS ITS: Vice President of Human Resources 	 
	 

	 	 	 	 	 
	Dated:  	5/25/11
 	 
	 	BioCrys(Pharmaceuticals, Inc. 	 
	 	4505 Emperor Blvd., Suite 200

Durham, NC 27703 	 
	 

 

 

Dear
Sir,

I,
THOMAS R. STAAB, II propose to bring to my BioCryst employment the following tangible materials and previously unpublished
documents, which materials and documents may be used in my BioCryst employment:

	 	 	 	 	 

	þ No materials

	 	o See below
	 	o Additional sheets attached

The signature below by a representative of my current or former employer confirms that my
continued possession and use of these materials is authorized.

AUTHORIZATION:

	 	 	 	 	 
	 	 
	Signature:  	/s/ [ILLEGIBLE]
 	 
	 	Title: VP HR 	 
	 	Employer: [ILLEGIBLE]exv4w1

EXHIBIT 4.1

Execution Version

EXHIBIT A

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES
ACT OF 1933, AS AMENDED (THE “U. S. SECURITIES ACT”). THE HOLDER HEREOF, BY PURCHASING SUCH
SECURITIES, AGREES FOR THE BENEFIT OF THE COMPANY THAT SUCH SECURITIES MAY BE OFFERED, SOLD OR
OTHERWISE TRANSFERRED WITHOUT REGISTRATION ONLY (A) TO THE COMPANY, (B) OUTSIDE THE UNITED STATES
IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES ACT, OR (C) WITHIN THE UNITED
STATES IN ACCORDANCE WITH (1) RULE 144A UNDER THE SECURITIES ACT OR (2) RULE 144 UNDER THE
SECURITIES ACT, IF AVAILABLE.

THE HOLDER, BY ITS ACCEPTANCE OF THIS SECURITY, REPRESENTS, ACKNOWLEDGES, AND AGREES THAT IT WILL
NOT AND WILL NOT BE ENTITLED TO, DIRECTLY OR INDIRECTLY, SELL OR TRANSFER THE SECURITIES INTO
CANADA OR TO RESIDENTS OF CANADA, EXCEPT IN COMPLIANCE WITH APPLICABLE CANADIAN SECURITIES LAWS.
NO SALE OR TRANSFER INTO CANADA OR TO A CANADIAN RESIDENT WILL BE REGISTERED BY THE COMPANY’S
TRANSFER AGENT AND ANY ATTEMPT TO EFFECT SUCH A TRANSFER IS INVALID UNLESS MADE IN COMPLIANCE WITH
THE ABOVE-NOTED RESTRICTIONS. UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS
SECURITY MUST NOT TRADE THE SECURITY BEFORE [4 MONTHS AND ONE DAY FROM CLOSING DATE].

COMMON STOCK PURCHASE WARRANT

MAD CATZ INTERACTIVE, INC.

			
	 	 	 
	Warrant Shares: [_______]
	 	Initial Exercise Date: October [____], 2011

Issue Date: April [____], 2011

          THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received,
_____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the
limitations on exercise and the conditions hereinafter set forth, at any time on or after the
six-month anniversary of the Issue Date (the “Initial Exercise Date”) and on or prior to
the close of business on the five-year anniversary of the Initial Exercise Date (the
“Termination Date”) but not thereafter, to subscribe for and purchase from Mad Catz
Interactive, Inc., a corporation organized under the Canada Business Corporations Act (the
“Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant
Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant
shall be equal to the Exercise Price, as defined in Section 2(b).

     Section 1. Definitions. Capitalized terms used and not otherwise defined
herein shall have the meanings set forth in that certain Securities Purchase Agreement (the
“Purchase Agreement”), dated April 17, 2011 (the “Subscription Date”), among the
Company and the purchasers signatory thereto.

 

 

     Section 2. Exercise.

     a) Exercise of Warrant. Exercise of the purchase rights represented by this
Warrant may be made, in whole or in part, at any time or times on or after the Initial
Exercise Date and on or before the Termination Date by delivery to the Company (or such
other office or agency of the Company as it may designate by notice in writing to the
registered Holder at the address of the Holder appearing on the books of the Company) of a
duly executed facsimile copy of the Notice of Exercise Form annexed hereto; and, within
three (3) Trading Days of the date said Notice of Exercise is delivered to the Company, the
Company shall have received payment of the aggregate Exercise Price of the shares specified
in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United
States bank or, if available and elected in the applicable Notice of Exercise, pursuant to
the cashless exercise procedure specified in Section 2(c) below. Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this
Warrant to the Company until the Holder has purchased all of the Warrant Shares available
hereunder and the Warrant has been exercised in full, in which case, the Holder shall
surrender this Warrant to the Company for cancellation within three (3) Trading Days of the
date the final Notice of Exercise is delivered to the Company. Partial exercises of this
Warrant resulting in purchases of a portion of the total number of Warrant Shares available
hereunder shall have the effect of lowering the outstanding number of Warrant Shares
purchasable hereunder in an amount equal to the applicable number of Warrant Shares
purchased. The Holder and the Company shall maintain records showing the number of Warrant
Shares purchased and the date of such purchases. The Company shall deliver any objection to
any Notice of Exercise Form within one (1) Business Day of receipt of such notice. The
Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by
reason of the provisions of this paragraph, following the purchase of a portion of the
Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at
any given time may be less than the amount stated on the face hereof.

     b) Exercise Price. The exercise price per share of the Common Stock under this
Warrant shall be $2.56, subject to adjustment hereunder (the “Exercise Price”).

     c) Cashless Exercise. If at the time of exercise hereof there is no effective
registration statement registering, or the prospectus contained therein is not available for
the issuance of the Warrant Shares to the Holder and all of the Warrant Shares are not then
registered for resale by the Holder into the market at market prices from time to time on an
effective registration statement for use on a continuous basis (or the prospectus contained
therein is not available for use), then this Warrant may also be exercised, in whole or in
part, at such time by means of a “cashless exercise” in which the Holder shall be entitled
to receive a certificate for the number of Warrant Shares equal to the quotient obtained by
dividing [(A-B) (X)] by (A), where:

	 	(A)	 	= the greater of the closing sale price for a share of Common
Stock or VWAP on the Trading Day immediately preceding the date on which Holder
elects

-2-

 

	 	 	 	to exercise this Warrant by means of a “cashless exercise,” as set forth in
the applicable Notice of Exercise;
	 
	 	(B)	 	= the Exercise Price of this Warrant, as adjusted hereunder;
and
	 
	 	(X)	 	= the number of Warrant Shares that would be issuable upon
exercise of this Warrant in accordance with the terms of this Warrant if such
exercise were by means of a cash exercise rather than a cashless exercise.

     “VWAP” means, for any date, the price determined by the first of the following
clauses that applies: (a) if the Common Stock is then listed or quoted on an Eligible
Market, the daily volume weighted average price of the Common Stock for such date (or the
nearest preceding date) on the Eligible Market on which the Common Stock is then listed or
quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time), (b) if the OTC Bulletin Board is not an Eligible
Market, the volume weighted average price of the Common Stock for such date (or the nearest
preceding date) on the OTC Bulletin Board, (c) if the Common Stock is not then listed or
quoted for trading on the OTC Bulletin Board and if prices for the Common Stock are then
reported in the “Pink Sheets” published by Pink OTC Markets, Inc. (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per
share of the Common Stock so reported, or (d) in all other cases, the fair market value of a
share of Common Stock as determined by an independent appraiser selected in good faith by
the Holders of a majority in interest of the Securities then outstanding and reasonably
acceptable to the Company, the fees and expenses of which shall be paid by the Company.

     Notwithstanding anything herein to the contrary, on the Termination Date, this Warrant,
to the extent not exercised prior thereto, shall be automatically exercised via cashless
exercise pursuant to this Section 2(c); provided, however, that (a) if this
Warrant is not then eligible for cashless exercise due to the provisions of the this Section
2(c), then upon the Company’s written request, the Holder shall pay to the Company the
aggregate Exercise Price in cash for all of the Warrant Shares exercised pursuant to this
paragraph, and (b) if the Holder fails to pay to the Company such Exercise Price within two
(2) Trading Days after such request, the automatic exercise of this Warrant pursuant to this
paragraph shall be null and void and the Company shall have no obligation to issue any such
Warrant Shares and the Holder shall immediately return any Warrant Shares previously issued
pursuant to this paragraph.

     d) Mechanics of Exercise.

     i. Delivery of Certificates Upon Exercise. Certificates for
shares purchased hereunder shall be transmitted by the Transfer Agent to the
Holder by crediting the account of the Holder’s prime broker with the
Depository Trust Company through its Deposit Withdrawal Agent Commission
(“DWAC”) system if the Company is then a participant in such system
and either (A) there is an effective Registration Statement

-3-

 

permitting the issuance of the Warrant Shares to, or resale of the
Warrant Shares, by the Holder, (B) the Warrant Shares are eligible for
resale by the Holder without volume or manner-of-sale limitations or (C)
this Warrant is being exercised via cashless exercise, and otherwise by
physical delivery to the address specified by the Holder in the Notice of
Exercise by the date that is three (3) Trading Days after the latest of (A)
the delivery to the Company of the Notice of Exercise Form, (B) surrender of
this Warrant (if required) and (C) payment of the aggregate Exercise Price
as set forth above (including by cashless exercise, if permitted) (such
date, the “Warrant Share Delivery Date”). This Warrant shall be
deemed to have been exercised on the date that the Notice of Exercise Form
is delivered to the Company. The Warrant Shares shall be deemed to have
been issued, and the Holder or any other person so designated to be named
therein shall be deemed to have become a holder of record of such shares for
all purposes, as of the date the Warrant has been exercised, with payment to
the Company of the Exercise Price (or by cashless exercise, if permitted)
and all taxes required to be paid by the Holder, if any, pursuant to Section
2(d)(vi) prior to the issuance of such shares, having been paid. If the
Company fails for any reason to deliver to the Holder certificates
evidencing the Warrant Shares subject to a Notice of Exercise by the Warrant
Share Delivery Date, the Company shall promptly pay to the Holder, in cash,
as liquidated damages and not as a penalty, for each $1,000 of Warrant
Shares subject to such exercise (based on the VWAP of the Common Stock on
the date of the applicable Notice of Exercise), $10 per Trading Day
(increasing to $20 per Trading Day on the fifth Trading Day after such
liquidated damages begin to accrue) for each Trading Day after such Warrant
Share Delivery Date until such certificates are delivered or Holder rescinds
such exercise.

     ii. Delivery of New Warrants Upon Exercise. If this Warrant
shall have been exercised in part, the Company shall, at the request of the
Holder and upon surrender of this Warrant certificate, at the time of
delivery of the certificate or certificates representing Warrant Shares,
deliver to the Holder a new Warrant evidencing the rights of the Holder to
purchase the unpurchased Warrant Shares called for by this Warrant, which
new Warrant shall in all other respects be identical with this Warrant.

     iii. Rescission Rights. If the Company fails to cause the
Transfer Agent to transmit to the Holder a certificate or the certificates
representing the Warrant Shares pursuant to Section 2(d)(i) by the Warrant
Share Delivery Date, then, the Holder will have the right to rescind such
exercise.

     iv. Compensation for Buy-In on Failure to Timely Deliver
Certificates Upon Exercise. In addition to any other rights available
to the

-4-

 

Holder, if the Company fails to cause the Transfer Agent to transmit to
the Holder a certificate or the certificates representing the Warrant Shares
pursuant to an exercise on or before the Warrant Share Delivery Date, and if
after such date the Holder is required by its broker to purchase (in an open
market transaction or otherwise) shares of Common Stock to deliver in
satisfaction of a sale by the Holder of the Warrant Shares which the Holder
anticipated receiving upon such exercise (a “Buy-In”), then the
Company shall, within three (3) Trading Days after the Holder’s request and
in the Holder’s discretion, either (i) pay cash to the Holder in an amount
equal to the Holder’s total purchase price (including brokerage commissions,
if any) for the shares of Common Stock so purchased (the “Buy-In
Price”), at which point the Company’s obligation to deliver such
certificate (and to issue such Warrant Shares or credit such Holder’s
balance account with DTC) shall terminate, or (ii) promptly honor its
obligation to deliver to the Holder a certificate or certificates
representing such Warrant Shares or credit such Holder’s balance account
with DTC and pay cash to the Holder in an amount equal to the excess (if
any) of the Buy-In Price over the product of (A) such number of shares of
Common Stock, times (B) the VWAP on the date of exercise.

     Nothing herein shall limit the Holder’s right to pursue any other
remedies available to it hereunder, at law or in equity, including, without
limitation, a decree of specific performance and/or injunctive relief with
respect to the Company’s failure to timely deliver certificates representing
shares of Common Stock upon exercise of the Warrant as required pursuant to
the terms hereof.

     v. No Fractional Shares or Scrip. No fractional shares or
scrip representing fractional shares shall be issued upon the exercise of
this Warrant. As to any fraction of a share which the Holder would
otherwise be entitled to purchase upon such exercise, the Company shall, at
its election, either pay a cash adjustment in respect of such final fraction
in an amount equal to such fraction multiplied by the Exercise Price or
round up to the next whole share.

     vi. Charges, Taxes and Expenses. Issuance of certificates for
Warrant Shares shall be made without charge to the Holder for any issue or
transfer tax or other incidental expense in respect of the issuance of such
certificate, all of which taxes and expenses shall be paid by the Company,
and such certificates shall be issued in the name of the Holder or in such
name or names as may be directed by the Holder; provided,
however, that in the event certificates for Warrant Shares are to be
issued in a name other than the name of the Holder, this Warrant when
surrendered for exercise shall be accompanied by the Assignment Form
attached hereto duly executed by the Holder and the Company may

-5-

 

require, as a condition thereto, the payment of a sum sufficient to
reimburse it for any transfer tax incidental thereto.

     vii. Closing of Books. The Company will not close its
stockholder books or records in any manner which prevents the timely
exercise of this Warrant, pursuant to the terms hereof.

     e) Holder’s Exercise Limitations. The Company shall not effect any exercise of
this Warrant, and the Holder shall not have the right to exercise any portion of this
Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such
issuance after exercise as set forth on the applicable Notice of Exercise, the Holder
(together with the Holder’s Affiliates, and any other Persons acting as a group together
with the Holder or any of the Holder’s Affiliates), would beneficially own in excess of the
Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its Affiliates
shall include the number of shares of Common Stock issuable upon exercise of this Warrant
with respect to which such determination is being made, but shall exclude the number of
shares of Common Stock which would be issuable upon (i) exercise of the remaining,
nonexercised portion of this Warrant beneficially owned by the Holder or any of its
Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any
other securities of the Company subject to a limitation on conversion or exercise analogous
to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates. Except as set forth in the preceding sentence, for purposes of this Section
2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the 1934
Act and the rules and regulations promulgated thereunder, it being acknowledged by the
Holder that the Company is not representing to the Holder that such calculation is in
compliance with Section 13(d) of the 1934 Act and the Holder is solely responsible for any
schedules required to be filed in accordance therewith. To the extent that the limitation
contained in this Section 2(e) applies, the determination of whether this Warrant is
exercisable (in relation to other securities owned by the Holder together with any
Affiliates) and of which portion of this Warrant is exercisable shall be in the sole
discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be
the Holder’s determination of whether this Warrant is exercisable (in relation to other
securities owned by the Holder together with any Affiliates) and of which portion of this
Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the
Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be
determined in accordance with Section 13(d) of the 1934 Act and the rules and regulations
promulgated thereunder. For purposes of this Section 2(e), in determining the number of
outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of
Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed
with the Commission, as the case may be, (B) a more recent public announcement by the
Company or (C) a more recent written notice by the Company or the Transfer Agent setting
forth the number of shares of Common Stock outstanding. Upon the written or oral request of
a Holder, the Company shall within two Trading Days confirm orally and in writing to the
Holder the number of shares of

-6-

 

Common Stock then outstanding. In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of
the Company, including this Warrant, by the Holder or its Affiliates since the date as of
which such number of outstanding shares of Common Stock was reported. The “Beneficial
Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of Common Stock
issuable upon exercise of this Warrant. The Holder, upon not less than 61 days’ prior
notice to the Company, may increase or decrease the Beneficial Ownership Limitation
provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no
event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant
held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any
such increase or decrease will not be effective until the 61st day after such
notice is delivered to the Company. The provisions of this paragraph shall be construed and
implemented in a manner otherwise than in strict conformity with the terms of this Section
2(e) to correct this paragraph (or any portion hereof) which may be defective or
inconsistent with the intended Beneficial Ownership Limitation herein contained or to make
changes or supplements necessary or desirable to properly give effect to such limitation.
The limitations contained in this paragraph shall apply to a successor holder of this
Warrant.

     Section 3. Certain Adjustments.

     a) Stock Dividends and Splits. If the Company, at any time while this Warrant
is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions
on shares of its Common Stock or any other equity or equity equivalent securities payable in
shares of Common Stock (which, for avoidance of doubt, shall not include any shares of
Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides
outstanding shares of Common Stock into a larger number of shares, (iii) combines (including
by way of reverse stock split) outstanding shares of Common Stock into a smaller number of
shares, or (iv) issues by reclassification of shares of the Common Stock any shares of
capital stock of the Company, then in each case the Exercise Price shall be multiplied by a
fraction of which the numerator shall be the number of shares of Common Stock (excluding
treasury shares, if any) outstanding immediately before such event and of which the
denominator shall be the number of shares of Common Stock outstanding immediately after such
event, and the number of shares issuable upon exercise of this Warrant shall be
proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain
unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective
immediately after the record date for the determination of stockholders entitled to receive
such dividend or distribution and shall become effective immediately after the effective
date in the case of a subdivision, combination or re-classification.

     b) Adjustment upon Issuance of Shares of Common Stock. If and whenever on or
after the date of the Purchase Agreement, the Company issues or sells, or in accordance with
this Section 3(b) is deemed to have issued or sold, any shares of

-7-

 

Common Stock (including the issuance or sale of shares of Common Stock owned or held by
or for the account of the Company) for a consideration per share (the “New Issuance
Price”) less than a price (the “Applicable Price”) equal to the Exercise Price
in effect immediately prior to such issue or sale or deemed issuance or sale (the foregoing
a “Dilutive Issuance”), then immediately after such Dilutive Issuance, the Exercise
Price then in effect shall be reduced and only reduced by multiplying the Exercise Price by
a fraction, the numerator of which is the number of shares of Common Stock issued and
outstanding immediately prior to the Dilutive Issuance plus the number of shares of Common
Stock which the offering price for such Dilutive Issuance would purchase at the then
Exercise Price, and the denominator of which shall be the sum of the number of shares of
Common Stock issued and outstanding immediately prior to the Dilutive Issuance plus the
number of shares of Common Stock so issued or issuable in connection with the Dilutive
Issuance. For purposes of determining the adjusted Exercise Price under this Section 2(a),
the following shall be applicable:

     (i) Issuance of Options. If the Company in any manner grants
any Options (as defined below), and the lowest price per share for which one
share of Common Stock is issuable upon the exercise of any such Option or
upon conversion, exercise or exchange of any Convertible Securities (as
defined below) issuable upon exercise of any such Option is less than the
Applicable Price, then such share of Common Stock shall be deemed to be
outstanding and to have been issued and sold by the Company at the time of
the granting or sale of such Option for such price per share. For purposes
of this Section 3(b)(i), the “lowest price per share for which one share of
Common Stock is issuable upon exercise of such Options or upon conversion,
exercise or exchange of such Convertible Securities issuable upon exercise
of any such Option” shall be equal to the sum of the lowest amounts of
consideration (if any) received or receivable by the Company with respect to
any one share of Common Stock upon the granting or sale of the Option, upon
exercise of the Option and upon conversion, exercise or exchange of any
Convertible Security issuable upon exercise of such Option. No further
adjustment of the Exercise Price shall be made upon the actual issuance of
such shares of Common Stock or of such Convertible Securities upon the
exercise of such Options or upon the actual issuance of such shares of
Common Stock upon conversion, exercise or exchange of such Convertible
Securities. “Options” means any rights, warrants or options to
subscribe for or purchase shares of Common Stock or Common Stock
Equivalents, other than any stock options issued pursuant to equity
compensation plans approved by the Company’s stockholders. “Convertible
Securities” means any stock or securities (other than Options)
convertible into or exercisable or exchangeable for shares of Common Stock
or Common Stock Equivalents. “Common Stock Equivalents” means any
securities of the Company or the Subsidiaries which would entitle the holder
thereof to acquire at any time Common Stock, including, without limitation,
any debt, preferred stock, right, option, warrant or other instrument that is at

-8-

 

any time convertible
into or exercisable or exchangeable for, or otherwise entitles the holder
thereof to receive, Common Stock.

     (ii) Issuance of Convertible Securities. If the Company in any
manner issues or sells any Convertible Securities, and the lowest price per
share for which one share of Common Stock is issuable upon the conversion,
exercise or exchange thereof is less than the Applicable Price, then such
share of Common Stock shall be deemed to be outstanding and to have been
issued and sold by the Company at the time of the issuance or sale of such
Convertible Securities for such price per share. For the purposes of this
Section 3(b)(ii), the “lowest price per share for which one share of Common
Stock is issuable upon the conversion, exercise or exchange thereof” shall
be equal to the sum of the lowest amounts of consideration (if any) received
or receivable by the Company with respect to one share of Common Stock upon
the issuance or sale of the Convertible Security and upon conversion,
exercise or exchange of such Convertible Security. No further adjustment of
the Exercise Price shall be made upon the actual issuance of such shares of
Common Stock upon conversion, exercise or exchange of such Convertible
Securities, and if any such issue or sale of such Convertible Securities is
made upon exercise of any Options for which adjustment of this Warrant has
been or is to be made pursuant to other provisions of this Section 3(b), no
further adjustment of the Exercise Price shall be made by reason of such
issue or sale.

     (iii) Change in Option Price or Rate of Conversion. If the
purchase price provided for in any Options, the additional consideration, if
any, payable upon the issue, conversion, exercise or exchange of any
Convertible Securities, or the rate at which any Convertible Securities are
convertible into or exercisable or exchangeable for shares of Common Stock
increases or decreases at any time, then the Exercise Price in effect at the
time of such increase or decrease shall be adjusted to the Exercise Price
which would have been in effect at such time had such Options or Convertible
Securities provided for such increased or decreased purchase price,
additional consideration or increased or decreased conversion rate, as the
case may be, at the time initially granted, issued or sold. For purposes of
this Section 3(b)(iii), if the terms of any Option or Convertible Security
that was outstanding as of the date of issuance of this Warrant are
increased or decreased in the manner described in the immediately preceding
sentence, then such Option or Convertible Security and the shares of Common
Stock deemed issuable upon exercise, conversion or exchange thereof shall be
deemed to have been issued as of the date of such increase or decrease. No
adjustment pursuant to this Section 3(b) shall be made if such adjustment
would result in an increase of the Exercise Price then in effect.

-9-

 

     (iv) Calculation of Consideration Received. If any shares of
Common Stock, Options or Convertible Securities are issued or sold or deemed
to have been issued or sold for cash, the consideration received therefor
will be deemed to be the net amount received by the Company therefor. If any
shares of Common Stock, Options or Convertible Securities are issued or sold
for a consideration other than cash, the amount of such consideration
received by the Company will be the fair value of such consideration, except
where such consideration consists of securities, in which case the amount of
consideration received by the Company will be the VWAP of such security on
the date of receipt. If any shares of Common Stock, Options or Convertible
Securities are issued to the owners of the non-surviving entity in
connection with any merger in which the Company is the surviving entity, the
amount of consideration therefor will be deemed to be the fair value of such
portion of the net assets and business of the non-surviving entity as is
attributable to such shares of Common Stock, Options or Convertible
Securities, as the case may be. The fair value of any consideration other
than cash or securities will be determined jointly by the Company and the
Holder. If such parties are unable to reach agreement within ten (10) days
after the occurrence of an event requiring valuation (the “Valuation
Event”), the fair value of such consideration will be determined within
five (5) Business Days after the tenth (10th) day following the
Valuation Event by an independent, reputable appraiser jointly selected by
the Company and the Holder. The determination of such appraiser shall be
final and binding upon all parties absent manifest error and the fees and
expenses of such appraiser shall be borne by the Company.

     (v) Record Date. If the Company takes a record of the holders
of shares of Common Stock for the purpose of entitling them (A) to receive a
dividend or other distribution payable in shares of Common Stock, Options or
in Convertible Securities or (B) to subscribe for or purchase shares of
Common Stock, Options or Convertible Securities, then such record date will
be deemed to be the date of the issue or sale of the shares of Common Stock
deemed to have been issued or sold upon the declaration of such dividend or
the making of such other distribution or the date of the granting of such
right of subscription or purchase, as the case may be.

     (vi) Compliance with TSX Rules. Notwithstanding the other
provisions of this Section 3(b), if such adjustment would result in an
adjusted Exercise Price that is less than the market price of the Company’s
Common Stock as such existed on the Issue Date of this Warrant, then the
Company, if required by the rules of the TSX, will promptly call and hold a
meeting of its stockholders to approve the reduction in the Exercise Price
as hereinbefore calculated, and the Company’s Board of Directors shall
recommend that the stockholders vote in favor of such approval. If

-10-

 

the Company’s stockholders do not approve such reduction in the Exercise
Price, the Company’s Board of Directors shall continue to recommend and seek
approval of such reduction at any scheduled meeting of the Company’s
stockholders, including at the annual stockholders meeting, or pursuant to
any proxy or written consent sought for any other purpose by the Company.

     c) Subsequent Rights Offerings. If the Company, at any time while the Warrant
is outstanding, shall issue rights, options or warrants to all holders of Common Stock (and
not to the Holders) entitling them to subscribe for or purchase shares of Common Stock at a
price per share less than the VWAP on the record date mentioned below, then, the Exercise
Price shall be multiplied by a fraction, of which the denominator shall be the number of
shares of the Common Stock outstanding on the date of issuance of such rights, options or
warrants plus the number of additional shares of Common Stock issued in such subscription or
purchase, and of which the numerator shall be the number of shares of the Common Stock
outstanding on the date of issuance of such rights, options or warrants plus the number of
shares which the aggregate offering price of the total number of shares so offered (assuming
receipt by the Company in full of all consideration payable upon exercise of such rights,
options or warrants) would purchase at such VWAP. Such adjustment shall be made whenever
such rights, options or warrants are issued, and shall become effective immediately after
the record date for the determination of stockholders entitled to receive such rights,
options or warrants.

     d) Pro Rata Distributions. If the Company, at any time while this Warrant is
outstanding, shall distribute to all holders of Common Stock (and not to the Holders)
evidences of its indebtedness or assets (including cash and cash dividends) or rights or
warrants to subscribe for or purchase any security other than the Common Stock (which shall
be subject to Section 3(b)), then in each such case the Exercise Price shall be adjusted by
multiplying the Exercise Price in effect immediately prior to the record date fixed for
determination of stockholders entitled to receive such distribution by a fraction of which
the denominator shall be the VWAP determined as of the record date mentioned above, and of
which the numerator shall be such VWAP on such record date less the then per share fair
market value at such record date of the portion of such assets or evidence of indebtedness
so distributed applicable to one outstanding share of the Common Stock as determined by the
Board of Directors in good faith. In either case the adjustments shall be described in a
statement provided to the Holder of the portion of assets or evidences of indebtedness so
distributed or such subscription rights applicable to one share of Common Stock. Such
adjustment shall be made whenever any such distribution is made and shall become effective
immediately after the record date mentioned above.

     e)
Fundamental Transaction. If, at any time while this Warrant is
outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the
Company, directly or indirectly, effects any sale, lease, license, assignment, transfer,
conveyance or other disposition of all or substantially all of its

-11-

 

assets in one or a series of related transactions, (iii) any, direct or indirect,
purchase offer, tender offer or exchange offer (whether by the Company or another Person) is
completed pursuant to which holders of Common Stock are permitted to sell, tender or
exchange their shares for other securities, cash or property and has been accepted by the
holders of 100% or more of the outstanding Common Stock, (iv) the Company, directly or
indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the Common Stock or any compulsory share exchange pursuant to which
the Common Stock is effectively converted into or exchanged for other securities, cash or
property, (v) the Company, directly or indirectly, in one or more related transactions
consummates a stock or share purchase agreement or other business combination (including,
without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement)
with another Person or group of Persons whereby such other Person or group acquires more
than 100% of the outstanding shares of Common Stock (not including any shares of Common
Stock held by the other Person or other Persons making or party to, or associated or
affiliated with the other Persons making or party to, such stock or share purchase agreement
or other business combination) (each a “Fundamental Transaction”), then, upon any
subsequent exercise of this Warrant, the Holder shall have the right to receive, for each
Warrant Share that would have been issuable upon such exercise immediately prior to the
occurrence of such Fundamental Transaction, at the option of the Holder (without regard to
any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of
Common Stock of the successor or acquiring corporation or of the Company, if it is the
surviving corporation, and any additional consideration (the “Alternate
Consideration”) receivable as a result of such Fundamental Transaction by a holder of
the number of shares of Common Stock for which this Warrant is exercisable immediately prior
to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the
exercise of this Warrant). For purposes of any such exercise, the determination of the
Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common
Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price
among the Alternate Consideration in a reasonable manner reflecting the relative value of
any different components of the Alternate Consideration. If holders of Common Stock are
given any choice as to the securities, cash or property to be received in a Fundamental
Transaction, then the Holder shall be given the same choice as to the Alternate
Consideration it receives upon any exercise of this Warrant following such Fundamental
Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental
Transaction other than one in which a Successor Entity (as defined below) that is a publicly
traded corporation whose stock is quoted or listed for trading on an Eligible Market assumes
this Warrant such that the Warrant shall be exercisable for the publicly traded Common Stock
of such Successor Entity, the Company or any Successor Entity shall, at the Holder’s
option, exercisable at any time concurrently with, or within 30 days after, the consummation
of the Fundamental Transaction, purchase this Warrant from the Holder by paying to the
Holder an amount of cash equal to the Black Scholes Value of the remaining unexercised
portion of this Warrant on the date of the consummation of such Fundamental Transaction. As
used herein (w) “Black Scholes Value” means the value of this Warrant based on the Black and Scholes Option Pricing Model obtained

-12-

 

from the “OV”
function on Bloomberg, L.P. (“Bloomberg”) determined as of the day of consummation
of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a
risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the
time between the date of the public announcement of the applicable Fundamental Transaction
and the Termination Date, (B) an expected volatility equal to the greater of 100% and the 90
day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately
following the public announcement of the applicable Fundamental Transaction, (C) the
underlying price per share used in such calculation shall be the sum of the price per share
being offered in cash, if any, plus the value of any non-cash consideration, if any, being
offered in such Fundamental Transaction and (D) a remaining option time equal to the time
between the date of the public announcement of the applicable Fundamental Transaction and
the Termination Date. The Company shall cause any successor entity in a Fundamental
Transaction in which the Company is not the survivor (the “Successor Entity”) to
assume in writing all of the obligations of the Company under this Warrant and the other
Transaction Documents in accordance with the provisions of this Section 3(e) pursuant to
written agreements in form and substance reasonably satisfactory to the Holder and approved
by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall,
at the option of the Holder, deliver to the Holder in exchange for this Warrant a security
of the Successor Entity evidenced by a written instrument substantially similar in form and
substance to this Warrant which is exercisable for a corresponding number of shares of
capital stock of such Successor Entity (or its parent entity) equivalent to the shares of
Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any
limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with
an exercise price which applies the exercise price hereunder to such shares of capital stock
(but taking into account the relative value of the shares of Common Stock pursuant to such
Fundamental Transaction and the value of such shares of capital stock, such number of shares
of capital stock and such exercise price being for the purpose of protecting the economic
value of this Warrant immediately prior to the consummation of such Fundamental
Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon
the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to,
and be substituted for (so that from and after the date of such Fundamental Transaction, the
provisions of this Warrant and the other Transaction Documents referring to the “Company”
shall refer instead to the Successor Entity), and may exercise every right and power of the
Company and shall assume all of the obligations of the Company under this Warrant and the
other Transaction Documents with the same effect as if such Successor Entity had been named
as the Company herein.

     f) Calculations. All calculations under this Section 3 shall be made to the
nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this
Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a
given date shall be the sum of the number of shares of Common Stock (excluding treasury
shares, if any) issued and outstanding.

     g) Notice to Holder.

-13-

 

     i. Adjustment to Exercise Price. Whenever the Exercise Price is
adjusted pursuant to any provision of this Section 3, the Company shall
promptly mail to the Holder a notice setting forth the Exercise Price after
such adjustment and setting forth a brief statement of the facts requiring
such adjustment.

     ii. Notice to Allow Exercise by Holder. After the Initial
Exercise Date, if (A) the Company shall declare a dividend (or any other
distribution in whatever form) on the Common Stock, (B) the Company shall
declare a special nonrecurring cash dividend on or a redemption of the
Common Stock, (C) the Company shall authorize the granting to all holders of
the Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any
stockholders of the Company shall be required in connection with any
reclassification of the Common Stock, any consolidation or merger to which
the Company is a party, any sale or transfer of all or substantially all of
the assets of the Company, or any compulsory share exchange whereby the
Common Stock is converted into other securities, cash or property, or (E)
the Company shall authorize the voluntary or involuntary dissolution,
liquidation or winding up of the affairs of the Company, then, in each case,
the Company shall cause to be mailed to the Holder at its last address as it
shall appear upon the Warrant Register of the Company, at least 20 calendar
days prior to the applicable record or effective date hereinafter specified,
a notice stating (x) the date on which a record is to be taken for the
purpose of such dividend, distribution, redemption, rights or warrants, or
if a record is not to be taken, the date as of which the holders of the
Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which
such reclassification, consolidation, merger, sale, transfer or share
exchange is expected to become effective or close, and the date as of which
it is expected that holders of the Common Stock of record shall be entitled
to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger,
sale, transfer or share exchange; provided that the failure to mail such
notice or any defect therein or in the mailing thereof shall not affect the
validity of the corporate action required to be specified in such notice.
To the extent that any notice provided hereunder constitutes, or contains,
material, non-public information regarding the Company or any of the
Subsidiaries, the Company shall simultaneously file such notice with the
Commission pursuant to a Current Report on Form 8-K. The Holder shall
remain entitled to exercise this Warrant during the period commencing on the
date of such notice to the effective date of the event triggering such
notice except as may otherwise be expressly set forth herein.

     Section 4. Transfer of Warrant.

-14-

 

     a) Transferability. Subject to compliance with any applicable securities laws,
this Warrant and all rights hereunder (including, without limitation, any registration
rights) are transferable, in whole or in part, upon surrender of this Warrant at the
principal office of the Company or its designated agent, together with a written assignment
of this Warrant substantially in the form attached hereto duly executed by the Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of
such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as
applicable, and in the denomination or denominations specified in such instrument of
assignment, and shall issue to the assignor a new Warrant evidencing the portion of this
Warrant not so assigned, and this Warrant shall promptly be cancelled. The Warrant, if
properly assigned in accordance herewith, may be exercised by a new holder for the purchase
of Warrant Shares without having a new Warrant issued.

     b) New Warrants. This Warrant may be divided or combined with other Warrants
upon presentation hereof at the aforesaid office of the Company, together with a written
notice specifying the names and denominations in which new Warrants are to be issued, signed
by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any
transfer which may be involved in such division or combination, the Company shall execute
and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges
shall be dated the initial issuance date set forth on the first page of this Warrant and
shall be identical with this Warrant except as to the number of Warrant Shares issuable
pursuant thereto.

     c) Warrant Register. The Company shall register this Warrant, upon records to
be maintained by the Company for that purpose (the “Warrant Register”), in the name
of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any
exercise hereof or any distribution to the Holder, and for all other purposes, absent actual
notice to the contrary.

     d) Representation by the Holder. The Holder, by the acceptance hereof,
represents and warrants that it is acquiring this Warrant and, upon any exercise hereof,
will acquire the Warrant Shares issuable upon such exercise, for its own account and not
with a view to or for distributing or reselling such Warrant Shares or any part thereof in
violation of the 1933 Act or any applicable state securities law, except pursuant to sales
registered or exempted under the 1933 Act.

     Section 5. Miscellaneous.

     a) No Rights as Stockholder Until Exercise. This Warrant does not entitle the
Holder to any voting rights, dividends or other rights as a stockholder of the Company prior
to the exercise hereof as set forth in Section 2(d)(i).

-15-

 

     b) Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants
that upon receipt by the Company of evidence reasonably satisfactory to it of the loss,
theft, destruction or mutilation of this Warrant or any stock certificate relating to the
Warrant Shares, and in case of loss, theft or destruction, of indemnity or security
reasonably satisfactory to it (which, in the case of the Warrant, shall not include the
posting of any bond), and upon surrender and cancellation of such Warrant or stock
certificate, if mutilated, the Company will make and deliver a new Warrant or stock
certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or
stock certificate.

     c) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the
taking of any action or the expiration of any right required or granted herein shall not be
a Business Day, then, such action may be taken or such right may be exercised on the next
succeeding Business Day.

     d) Authorized Shares.

               The Company covenants that, during the period the Warrant is outstanding, it
will reserve from its authorized and unissued Common Stock a sufficient number of
shares to provide for the issuance of the Warrant Shares upon the exercise of any
purchase rights under this Warrant. The Company further covenants that its issuance
of this Warrant shall constitute full authority to its officers who are charged with
the duty of executing stock certificates to execute and issue the necessary
certificates for the Warrant Shares upon the exercise of the purchase rights under
this Warrant. The Company will take all such reasonable action as may be necessary
to assure that such Warrant Shares may be issued as provided herein without
violation of any applicable law or regulation, or of any requirements of the
Eligible Market upon which the Common Stock may be listed. The Company covenants
that all Warrant Shares which may be issued upon the exercise of the purchase rights
represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly
authorized, validly issued, fully paid and nonassessable and free from all taxes,
liens and charges created by the Company in respect of the issue thereof (other than
taxes in respect of any transfer occurring contemporaneously with such issue).

               Except and to the extent as waived or consented to by the Holder, the Company
shall not by any action, including, without limitation, amending its certificate of
incorporation or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such
terms and in the taking of all such actions as may be necessary or appropriate to
protect the rights of the Holder as set forth in this Warrant against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase
the par value of any Warrant Shares above the amount payable

-16-

 

therefor upon such exercise immediately prior to such increase in par value,
(ii) take all such action as may be necessary or appropriate in order that the
Company may validly and legally issue fully paid and nonassessable Warrant Shares
upon the exercise of this Warrant and (iii) use commercially reasonable efforts to
obtain all such authorizations, exemptions or consents from any public regulatory
body having jurisdiction thereof, as may be, necessary to enable the Company to
perform its obligations under this Warrant.

     Before taking any action which would result in an adjustment in the number of
Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the
Company shall obtain all such authorizations or exemptions thereof, or consents
thereto, as may be necessary from any public regulatory body or bodies having
jurisdiction thereof.

     e) Jurisdiction. All questions concerning the construction, validity,
enforcement and interpretation of this Warrant shall be determined in accordance with the
provisions of the Purchase Agreement.

     f) Restrictions. The Holder acknowledges that the Warrant Shares acquired upon
the exercise of this Warrant, if not registered and the Holder does not utilize cashless
exercise, will have restrictions upon resale imposed by state, provincial and federal
securities laws.

     g) Nonwaiver and Expenses. No course of dealing or any delay or failure to
exercise any right hereunder on the part of the Holder shall operate as a waiver of such
right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any
other provision of this Warrant or the Purchase Agreement, if the Company willfully and
knowingly fails to comply with any provision of this Warrant, which results in any material
damages to the Holder, the Company shall pay to the Holder such amounts as shall be
sufficient to cover any costs and expenses, including, but not limited to, reasonable
attorneys’ fees, including those of appellate proceedings, incurred by the Holder in
collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights,
powers or remedies hereunder.

     h) Notices. Any notice, request or other document required or permitted to be
given or delivered to the Holder by the Company shall be delivered in accordance with the
notice provisions of the Purchase Agreement.

     i) Limitation of Liability. No provision hereof, in the absence of any
affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no
enumeration herein of the rights or privileges of the Holder, shall give rise to any
liability of the Holder for the purchase price of any Common Stock or as a stockholder of
the Company, whether such liability is asserted by the Company or by creditors of the
Company.

     j) Remedies. The Holder, in addition to being entitled to exercise all rights
granted by law, including recovery of damages, will be entitled to specific performance

-17-

 

of
its rights under this Warrant. The Company agrees that monetary damages would not be
adequate compensation for any loss incurred by reason of a breach by it of the provisions of
this Warrant and hereby agrees to waive and not to assert the defense in any action for
specific performance that a remedy at law would be adequate.

     k) Successors and Assigns. Subject to applicable securities laws, this Warrant
and the rights and obligations evidenced hereby shall inure to the benefit of and be binding
upon the successors and permitted assigns of the Company and the successors and permitted
assigns of the Holder. The provisions of this Warrant are intended to be for the benefit of
any Holder from time to time of this Warrant and shall be enforceable by the Holder or
holder of Warrant Shares.

     l) Amendment. This Warrant may be modified or amended or the provisions hereof
waived with the written consent of the Company and the Holder.

     m) Severability. Wherever possible, each provision of this Warrant shall be
interpreted in such manner as to be effective and valid under applicable law, but if any
provision of this Warrant shall be prohibited by or invalid under applicable law, such
provision shall be ineffective to the extent of such prohibition or invalidity, without
invalidating the remainder of such provisions or the remaining provisions of this Warrant.

     n) Headings. The headings used in this Warrant are for the convenience of
reference only and shall not, for any purpose, be deemed a part of this Warrant.

     o) Currency. All references to “dollars” or “$” or “US$” in this Warrant refer
to United States dollars, which is the currency used for all purposes in this Warrant.

********************

(Signature Pages Follow)

-18-

 

     IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer
thereunto duly authorized as of the date first above indicated.

	 	 	 	 	 
	 	MAD CATZ INTERACTIVE, INC.

 	 
	 	By:  	 	 
	 	 	Name:  	 	 
	 	 	Title:  	 	 

-19-

 

NOTICE OF EXERCISE

TO: MAD CATZ INTERACTIVE, INC.

          (1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant
to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of
the exercise price in full, together with all applicable transfer taxes, if any.

          (2) Payment shall take the form of (check applicable box):

o in lawful money of the United States; or

oif permitted] the cancellation of such number of Warrant Shares as is
necessary, in accordance with the formula set forth in subsection 2(c), to
exercise this Warrant with respect to the maximum number of Warrant Shares
purchasable pursuant to the cashless exercise procedure set forth in subsection
2(c).

          (3) Please issue a certificate or certificates representing said Warrant Shares in the name of
the undersigned or in such other name as is specified below:

_____________________

The Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery
of a certificate to:

_____________________

_____________________

_____________________

[SIGNATURE OF HOLDER]

Name of Investing Entity: 

Signature of Authorized Signatory of Investing Entity: 

Name of Authorized Signatory: 

Title of Authorized Signatory: 

Date: 

 

 

ASSIGNMENT FORM

(To assign the foregoing warrant, execute

this form and supply required information.

Do not use this form to exercise the warrant.)

          FOR VALUE RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all rights
evidenced thereby are hereby assigned to

_______________________________________________ whose address is

______________________________________________________________.

_______________________________________________________________

Dated: ______________, _______

Holder’s Signature: _______________________________________

Holder’s Address: ________________________________________

________________________________________

Signature Guaranteed: _______________________________________________

NOTE: The signature to this Assignment Form must correspond with the name as it appears on the
face of the Warrant, without alteration or enlargement or any change whatsoever, and must be
guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or
other representative capacity should file proper evidence of authority to assign the foregoing
Warrant.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00192-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00192-of-00352.parquet"}]]